Biomaterials · 2018 · 32 citations · 76 references
Life SciencesBioengineeringBiotechnologyNanobiotechnologyNanomaterialsNanotechnologyCell-nanoparticle InteractionsNanomedicineNanoparticle DesignNanostructured BiomaterialsProtein-based NanomaterialsSurface Functionalization Of NanomaterialsCell-nanomaterial InteractionsMultifunctional NanomaterialsNanobiomaterial InterfacesNanocrystalsNanoparticle InteractionsNanoparticle-biomolecule InteractionsNanoparticlesNanostructure-cell Interactions
The blocking of specific protein-protein interactions using nanoparticles is an emerging alternative to small molecule-based therapeutic interventions. However, the nanoparticles designed as "artificial proteins" generally require modification of their surface with (bio)organic molecules and/or polymers to ensure their selectivity and specificity of action. Here, we show that nanosized diamond crystals (nanodiamonds, NDs) without any synthetically installed (bio)organic interface enable the specific and efficient targeting of the family of extracellular signalling molecules known as fibroblast growth factors (FGFs). We found that low nanomolar solutions of detonation NDs with positive ζ-potential strongly associate with multiple FGF ligands present at sub-nanomolar concentrations and effectively neutralize the effects of FGF signalling in cells without interfering with other growth factor systems and serum proteins unrelated to FGFs. We identified an evolutionarily conserved FGF recognition motif, ∼17 amino acids long, that contributes to the selectivity of the ND-FGF interaction. In addition, we inserted this motif into a de novo constructed chimeric protein, which significantly improved its interaction with NDs. We demonstrated that the interaction of NDs, as purely inorganic nanoparticles, with proteins can mitigate pathological FGF signalling and promote the restoration of cartilage growth in a mouse limb explant model. Based on our observations, we foresee that NDs may potentially be applied as nanotherapeutics to neutralize disease-related activities of FGFs in vivo.
76
Tommy Cedervall, Iseult Lynch, Stina Lindman et al. · Proceedings of the National Academy of Sciences · 2007 · 3.2K citations · Full text
Protein-nanoparticle interactions
Iseult Lynch, Kenneth A. Dawson · Nano Today · 2008 · 1.7K citations
Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth
Anthony Wynshaw‐Boris, Fen Zhou, Ann Kuo et al. · Cell · 1996 · 1.1K citations · Full text
TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4
The EMBO Journal · 1997 · 1.1K citations · Full text